/PRNewswire/ ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for.
ThirtyFiveBio aims to treat gastrointestinal cancer by targeting a so-called orphan receptor called GPR35. The biotech startup is revealing its science at the American Association of Cancer Research annual meeting.
/PRNewswire/ ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for.